Form 4 ACADIA PHARMACEUTICALS For: Feb 23 Filed by: Teehan Brendan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'
February 28, 2024 6:15 AM ESTMizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "With investor focus on the Daybue launch, ACAD will likely trade down today. We would buy on weakness. Investors... More
